LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Dynogen developed a portfolio of therapies for gastrointestinal and genitourinary disorders. It went out of business in 2009.
Dynogen Pharmaceuticals
Waltham, MA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.